CALA Calithera Biosciences Inc

On June 1, 2022, Calithera Biosciences, Inc. (“Calithera”) held its 2022 Virtual Annual Meeting of Stockholders (the “Annual Meeting”) via live webcast originating from South San Francisco, California. At the Annual Meeting, Calithera’s stockholders voted on five proposals, each of which is described in more detail in Calithera’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 20, 2022. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

Proposal 1. Stockholders elected the two nominees for Class II directors to serve until Calithera’s 2025 Annual Meeting of Stockholders or until her respective successor has been duly elected and qualified. The voting results were as follows:

Proposal 2. Stockholders ratified the selection by the Audit Committee of the Board of Directors of Calithera of Ernst & Young LLP as Calithera’s independent registered public accounting firm for the year ending December 31, 2022. The voting results were as follows:

Proposal 3. Stockholders approved, on an advisory basis, the compensation of the Calithera’s named executive officers, as disclosed in the proxy statement. The voting results were as follows:

Proposal 4. Stockholders approved an amendment to our certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock, as disclosed in the proxy statement. The voting results were as follows:

Proposal 5. Stockholders approved the issuance of more than 20% of our issued and outstanding common stock, as disclosed in the proxy statement. The voting results were as follows: